Direxion Daily S&P Biotech Bear 3X ETF
LABD
21 hedge funds and large institutions have $18.5M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 4 closing their positions.
1,000% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 1
149% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $4.15M
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
64% more capital invested
Capital invested by funds: $11.3M → $18.5M (+$7.22M)
41.65% more ownership
Funds ownership: 16.94% → 58.59% (+42%)
24% more funds holding
Funds holding: 17 → 21 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$9.42M |
| 2 |
HF
HRT Financial
New York
|
+$3.42M |
| 3 |
Goldman Sachs
New York
|
+$3.28M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$1.4M |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$831K |
| 2 |
CCM
Capstone Capital Management
Hong Kong,
|
-$674K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$281K |
| 4 |
IMC Chicago
Chicago,
Illinois
|
-$168K |
| 5 |
Morgan Stanley
New York
|
-$9.78K |
LABD Hedge Fund Activity: Q2 2026 in Review
21 of the 8,335 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2026, worth a combined $18.5M — up 64% from $11.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LABD positions and 4 closed out — a net gain of 4 holders — while 11 added to existing stakes and 1 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $9.42M. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $831K sold.
- 21 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2026, up from 17 in Q1 2026.
- Funds reported $18.5M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2026, up 64% quarter-over-quarter.
- 8 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2026 and 4 closed out, a net change of +4 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2026 was BNP Paribas Financial Markets, an estimated $9.42M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2026 was Cantor Fitzgerald, an estimated $831K sold.
Based on aggregated 13F filings for Q2 2026.